- Home
- CRIS
CRIS
Curis Inc.
as 04-23-2025 4:00pm EST
Curis Inc is a biotechnology company that develops and commercializes drugs and therapies in the immuno-oncology and precision oncology therapeutic areas. The company targets solid tumors, diffuse large B-cell lymphoma, solid tumors or lymphomas, hematological cancers, and others. Its pipeline products include Fimepinostat, CA-170, CA-4948, CA-327, and Erivedge.
| Founded: | 2000 | Country: | United States |
| Employees: | 33 | City: | LEXINGTON |
| Market Cap: | 13.5M | IPO Year: | 2000 |
| Target Price: | $21.00 | AVG Volume (30 days): | 102.7K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 3 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -6.88 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.02 - $16.99 | Next Earning Date: | 05-06-2025 |
| Revenue: | $10,908,000 | Revenue Growth: | 8.83% |
| Revenue Growth (this year): | 2.33% | Revenue Growth (next year): | 9.78% |
Latest Curis Inc. News
CRIS Breaking Stock News: Dive into CRIS Ticker-Specific Updates for Smart Investing
Simply Wall St.
21 days ago
Analyst Forecasts For Curis, Inc. (NASDAQ:CRIS) Are Surging Higher
PR Newswire
21 days ago
Curis to Present at Upcoming Healthcare Conference in April
Simply Wall St.
23 days ago
Curis, Inc. (NASDAQ:CRIS) Just Reported Full-Year Earnings And Analysts Are Lifting Their Estimates
GuruFocus.com
23 days ago
Curis Inc (CRIS) Q4 2024 Earnings Call Highlights: Financial Improvements and Promising ...
Thomson Reuters StreetEvents
23 days ago
Q4 2024 Curis Inc Earnings Call
Associated Press Finance
24 days ago
Curis: Q4 Earnings Snapshot
PR Newswire
24 days ago
Curis Provides Fourth Quarter 2024 Business Update
Simply Wall St.
25 days ago
Curis Full Year 2024 Earnings: Revenues Beat Expectations, EPS In Line
Compare CRIS vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "CRIS Curis Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.